A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: liraglutide; Drug: sitagliptin

Study type: Observational

Funder types: Industry

Identifiers

NCT02077946

U1111-1151-9632 (Other Identifier)

NN2211-4161

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this study is to investigate a retrospective database assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide from primary care centers in Sweden.

Enrollment: 1,059 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients from EMR (electronic medical record) system in the primary care in Sweden
• Patients equal to or more than 18 years of age
• Starting treatment with liraglutide or sitagliptin from January 2010 to December 2013
• Minimum of 180 days of prior follow-up/history within the database before their index date

Exclusion criteria

• Patients with cancer, end stage liver disease, end stage renal failure (non-diabetes related)
• Female patients with gestational diabetes during pregnancy
• Patients with previous GLP-1 (glucagon-like peptide-1) or DPP-IV (dipeptidyl peptidase-4 ) inhibitor use, i.e. patients should be incretin naïve

Trial design

1,059 participants in 1 patient group

Liraglutide / Sitagliptin

Treatment:

Drug: sitagliptin

Drug: liraglutide